Author: Ravi Shankar

ATHENS, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it will release its financial results for the third quarter ended September 30, 2026, on November 17, 2026 before market opens in New York.

On the same day, Tuesday, November 17, 2026, at 9:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results.

Conference Call details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID13763766. Click here for additional participant International Toll -Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Audio Webcast– Slides Presentation:

There will be a live and then archived webcast of the conference call and accompanying slides, available on the Company’s website. To listen to the archived audio file, visit our website http://www.euroseas.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation for the third quarter ended September 30, 2026, will also be available in PDF format minutes prior to the conference call and webcast, accessible on the company’s website (www.euroseas.gr) on the webcast page. Participants to the webcast can download the PDF presentation.

About EuroseasLtd.

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 150 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA.
Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

After the sale of M/V Evridiki G, the Company will have a fleet of 20 vessels, including 14 Feeder containership and 6 Intermediate containerships with a cargo capacity of 58,588 teu. After the delivery of four intermediate and eight feeder containership newbuildings between 2027 and 2029, Euroseas’ fleet will consist of 32 vessels with a total carrying capacity of 94,840 teu.

Visit the Company’s website www.euroseas.gr

Company Contact Investor Relations / Financial Media

Tasos Aslidis
Chief Financial Officer Euroseas Ltd.
11 Canterbury Lane,
Watchung, NJ 07069
Tel. (908) 301-9091
E-mail: aha@euroseas.gr

Nicolas Bornozis Markella Kara Capital Link, Inc.
230 Park Avenue, Suite 1540 New York, NY 10169
Tel. (212) 661-7566
E-mail: euroseas@capitallink.com

ATHENS, Greece, Nov. 12, 2026 (GLOBE NEWSWIRE) — Euroseas Ltd. (NASDAQ: ESEA), an owner and operator of container carrier vessels and provider of seaborne transportation for containerized cargoes, announced today that it will release its financial results for the third quarter ended September 30, 2026, on November 17, 2026 before market opens in New York.

On the same day, Tuesday, November 17, 2026, at 9:30 a.m. Eastern Time, the Company’s management will host a conference call and webcast to discuss the results.

Conference Call details:

Participants should dial into the call 10 minutes before the scheduled time using the following numbers: 877 405 1226 (US Toll-Free Dial In) or +1 201 689 7823 (US and Standard International Dial In). Please quote “Euroseas” to the operator and/or conference ID13763766. Click here for additional participant International Toll -Free access numbers.

Alternatively, participants can register for the call using the call me option for a faster connection to join the conference call. You can enter your phone number and let the system call you right away. Click here for the call me option.

Audio Webcast– Slides Presentation:

There will be a live and then archived webcast of the conference call and accompanying slides, available on the Company’s website. To listen to the archived audio file, visit our website http://www.euroseas.gr and click on Company Presentations under our Investor Relations page. Participants to the live webcast should register on the website approximately 10 minutes prior to the start of the webcast.

The slide presentation for the third quarter ended September 30, 2026, will also be available in PDF format minutes prior to the conference call and webcast, accessible on the company’s website (www.euroseas.gr) on the webcast page. Participants to the webcast can download the PDF presentation.

About EuroseasLtd.

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 150 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA.
Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

After the sale of M/V Evridiki G, the Company will have a fleet of 20 vessels, including 14 Feeder containership and 6 Intermediate containerships with a cargo capacity of 58,588 teu. After the delivery of four intermediate and eight feeder containership newbuildings between 2027 and 2029, Euroseas’ fleet will consist of 32 vessels with a total carrying capacity of 94,840 teu.

Visit the Company’s website www.euroseas.gr

Company Contact Investor Relations / Financial Media

Tasos Aslidis
Chief Financial Officer Euroseas Ltd.
11 Canterbury Lane,
Watchung, NJ 07069
Tel. (908) 301-9091
E-mail: aha@euroseas.gr

Nicolas Bornozis Markella Kara Capital Link, Inc.
230 Park Avenue, Suite 1540 New York, NY 10169
Tel. (212) 661-7566
E-mail: euroseas@capitallink.com

TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group,” “Altus” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced that its Chair and CEO Mike Gordon has been named a 2026 Inspiring Leader, by the Inspiring Workplaces Group (IWG) in partnership with RADICL.

The Inspiring Leaders Awards recognize global leaders who make a meaningful difference to their people, their organizations, and the cultures they help to create. Backed by employee testimonials, the winners are recognized for their ability to inspire belief, build trust, create belonging and empower their people.

Since returning as CEO in 2026, Mike has led Altus through a period of significant transformation, with an emphasis on clarity, transparency and connection across the organization. As Altus evolved into a more focused data and analytics platform, he has worked to bring employees along on that journey, translating the Company’s strategy into clear priorities, communicating openly about progress and change, and helping employees understand the role they play in Altus’ success.

“Mike has an incredible ability to help people understand where we’re headed, while creating meaningful opportunities for them to shape the path forward,” said Kim Carter, Chief People Officer, Altus Group. “He gives people real ownership and sets a high bar for performance, and great talent thrives on that. Everyone at Altus knows our goals, why their role matters and how it serves the customer, and it shows in a more accountable, entrepreneurial, execution-focused organization.”

Mike continues to champion Altus’ high-trust, high-performance culture that empowers employees, drives industry-leading innovation and delivers value to our customers.

About Altus Group 

Altus Group is a leading provider of commercial real estate (“CRE”) intelligence, anchored by ARGUS – the industry’s go-to software for valuation and performance analytics. For more than two decades, Altus has played a vital role in empowering CRE professionals with the analytics and trusted advice they need to make high-stakes decisions with confidence. The world’s CRE leaders rely on our market-leading solutions and expertise to drive performance and manage risk. Our people around the world are making a lasting impact on an industry undergoing unprecedented change – helping shape the cities where we live, work, and build thriving communities. For more information about Altus (TSX: AIF) please visit www.altusgroup.com.

FOR FURTHER INFORMATION PLEASE CONTACT: 

Camilla Bartosiewicz 
Chief Communications Officer, Altus Group 
(416) 641-9773 
camilla.bartosiewicz@altusgroup.com

TORONTO, Nov. 12, 2026 (GLOBE NEWSWIRE) — Altus Group Limited (“Altus Group,” “Altus” or the “Company”) (TSX: AIF), a leading provider of commercial real estate (“CRE”) intelligence, today announced that its Chair and CEO Mike Gordon has been named a 2026 Inspiring Leader, by the Inspiring Workplaces Group (IWG) in partnership with RADICL.

The Inspiring Leaders Awards recognize global leaders who make a meaningful difference to their people, their organizations, and the cultures they help to create. Backed by employee testimonials, the winners are recognized for their ability to inspire belief, build trust, create belonging and empower their people.

Since returning as CEO in 2026, Mike has led Altus through a period of significant transformation, with an emphasis on clarity, transparency and connection across the organization. As Altus evolved into a more focused data and analytics platform, he has worked to bring employees along on that journey, translating the Company’s strategy into clear priorities, communicating openly about progress and change, and helping employees understand the role they play in Altus’ success.

“Mike has an incredible ability to help people understand where we’re headed, while creating meaningful opportunities for them to shape the path forward,” said Kim Carter, Chief People Officer, Altus Group. “He gives people real ownership and sets a high bar for performance, and great talent thrives on that. Everyone at Altus knows our goals, why their role matters and how it serves the customer, and it shows in a more accountable, entrepreneurial, execution-focused organization.”

Mike continues to champion Altus’ high-trust, high-performance culture that empowers employees, drives industry-leading innovation and delivers value to our customers.

About Altus Group 

Altus Group is a leading provider of commercial real estate (“CRE”) intelligence, anchored by ARGUS – the industry’s go-to software for valuation and performance analytics. For more than two decades, Altus has played a vital role in empowering CRE professionals with the analytics and trusted advice they need to make high-stakes decisions with confidence. The world’s CRE leaders rely on our market-leading solutions and expertise to drive performance and manage risk. Our people around the world are making a lasting impact on an industry undergoing unprecedented change – helping shape the cities where we live, work, and build thriving communities. For more information about Altus (TSX: AIF) please visit www.altusgroup.com.

FOR FURTHER INFORMATION PLEASE CONTACT: 

Camilla Bartosiewicz 
Chief Communications Officer, Altus Group 
(416) 641-9773 
camilla.bartosiewicz@altusgroup.com

Châtillon, France, November 12, 2026

DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN^® Peanut Patch in Children Ages 4-7 Years

• Additional VITESSE data being presented at 2026 ACAAI Annual Scientific Meeting support safety and efficacy findings from the phase 3 study, and assess potential practical aspects of daily use if approved
• VIASKIN^® Peanut Patch treatment was associated with statistically significant reductions in reaction severity during the double-blind, placebo-controlled food challenges after 12 months, including reductions when reactions were assessed at or below participants’ baseline eliciting dose
• Mean treatment compliance was 96.1%; most study participants reported patches were easy and not painful to remove, and no restrictions on daily activities or concomitant medications were required in the study protocol
• VITESSE participants receiving the VIASKIN^® Peanut Patch had immunologic changes consistent with allergen immunotherapy, including increased peanut-specific IgG4 and decreased peanut-specific IgE, Ara h 2 IgE and skin-prick-test wheal diameter

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that new data from the successful Phase 3 VITESSE clinical trial of the VIASKIN^® Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. The three presentations evaluate changes in allergic reaction severity during double-blind, placebo-controlled food challenges, the potential practicality of the VIASKIN® Peanut Patch using epicutaneous immunotherapy (EPIT), and changes to immunologic biomarkers during the 12-month VITESSE study.

VITESSE, the largest food allergy immunotherapy trial to date, randomized 654 children 2:1 to receive the VIASKIN Peanut Patch containing 250 µg of peanut protein (VP250) or placebo for 12 months. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut Patch arm meeting treatment responder criteria at month 12 compared with 14.8% in the placebo arm (difference in response rates = 31.8%; 95% confidence interval [CI]: 24.5%, 39.0%; p<0.001).

“The VITESSE data presented at ACAAI add important context to the study’s overall positive results,” said Pharis Mohideen, M.D., Chief Medical Officer of DBV Technologies. “After one year of treatment, children receiving the VIASKIN® Peanut Patch in the study had statistically significantly lower maximum symptom severity during food challenge, along with immunologic changes consistent with other forms of allergen immunotherapy. I am also pleased that the practicality data show high treatment compliance in young children with common atopic comorbidities, and that all participants were able to continue their typical daily activities, including bathing, sports and swimming, while on treatment.”

Highlights from the VITESSE data presented at ACAAI 2026:
“Changes in Reaction Severity Following Epicutaneous Immunotherapy in Children with Peanut Allergy”

• At the month 12 double-blind, placebo-controlled food challenge (DBPCFC), maximum symptom severity was significantly lower with the VIASKIN^® Peanut Patch versus placebo (p=0.004). Severe reactions occurred in 8.4% of VIASKIN treated participants versus 12.5% of placebo participants; 12.5% of VIASKIN treated participants had no or mild symptoms versus 1.5% with placebo.
• When reactions at month 12 were evaluated at or below each participant’s baseline eliciting dose, 52.7% of VIASKIN treated participants had no symptoms versus 19.2% with placebo, while moderate or severe reactions occurred in 14.0% of VIASKIN treated participants versus 50.0% with placebo.

“Immunologic Changes in VITESSE: A 12-Month Study of Epicutaneous Immunotherapy in Children with Peanut Allergy”

• Peanut-specific IgG4 increased by month 3 with the VIASKIN® Peanut Patch and remained elevated through month 12
• At month 12, median peanut-specific IgE and Ara 2-specific IgE were significantly lower with the VIASKIN® Peanut Patch versus placebo (p=0.001).
• Mean skin-prick-test wheal diameter decreased significantly with the VIASKIN® Peanut Patch versus placebo at month 12 (least-squares mean ratio: 0.74; 95% CI: 0.69, 0.79; p<0.0001).
• VIASKIN® Peanut Patch treatment for one year resulted in statistically significant greater responder rates versus placebo and immunomodulatory changes consistent with other forms of allergen immunotherapy.

“Practicality of Daily Epicutaneous Immunotherapy in Young Children with Peanut Allergy”

• Mean treatment compliance was high in both groups (96.1% with the VIASKIN® Peanut Patch and 96.5% with placebo).
• Most patches were rated by participants as “very easy” or “easy” to remove (83.4% with the VIASKIN® Peanut Patch; 84.8% with placebo) and “not painful” to remove (71.9% with the VIASKIN® Peanut Patch; 70.2% with placebo).
• Participants continued typical daily activities, including bathing/showering, play, sports and swimming, with no restrictions on daily activities or concomitant medication use required during the study.
• Atopic comorbidities were common among VITESSE participants, including atopic dermatitis, other food allergies and asthma.

“When I work with families in the clinic, the treatment conversations are not just about safety and efficacy, but practical considerations such as time commitment, how a treatment might fit into family life and family routines, and impact on the child,” said Edwin H. Kim, M.D., Associate Professor of Pediatrics at the University of North Carolina School of Medicine. “These additional data from VITESSE are clinically meaningful and I believe support the potential of the VIASKIN® Peanut Patch to be integrated into the daily routines of children living with peanut allergy, if approved.”

The presentations will be made available on the Scientific Publications & Presentations page on the Company’s website following presentation at the meeting.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN^® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN^® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements
This press release may contain forward-looking statements, including statements regarding the therapeutic potential of VIASKIN^® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, clinical trial data release and publications, , and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by the Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, DBV’s Quarterly Report on Form 10-Q filed with the SEC on October 28, 2026, and future filings and reports made with the SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Virginie Boucinha
DBV Technologies
Virginie.Boucinha@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

Châtillon, France, November 12, 2026

DBV Technologies Highlights New Data from the VITESSE Phase 3 Study of the VIASKIN^® Peanut Patch in Children Ages 4-7 Years

• Additional VITESSE data being presented at 2026 ACAAI Annual Scientific Meeting support safety and efficacy findings from the phase 3 study, and assess potential practical aspects of daily use if approved
• VIASKIN^® Peanut Patch treatment was associated with statistically significant reductions in reaction severity during the double-blind, placebo-controlled food challenges after 12 months, including reductions when reactions were assessed at or below participants’ baseline eliciting dose
• Mean treatment compliance was 96.1%; most study participants reported patches were easy and not painful to remove, and no restrictions on daily activities or concomitant medications were required in the study protocol
• VITESSE participants receiving the VIASKIN^® Peanut Patch had immunologic changes consistent with allergen immunotherapy, including increased peanut-specific IgG4 and decreased peanut-specific IgE, Ara h 2 IgE and skin-prick-test wheal diameter

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a late-stage biopharmaceutical company, today announced that new data from the successful Phase 3 VITESSE clinical trial of the VIASKIN^® Peanut Patch in peanut-allergic children aged 4 to 7 years were highlighted in three presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. The three presentations evaluate changes in allergic reaction severity during double-blind, placebo-controlled food challenges, the potential practicality of the VIASKIN® Peanut Patch using epicutaneous immunotherapy (EPIT), and changes to immunologic biomarkers during the 12-month VITESSE study.

VITESSE, the largest food allergy immunotherapy trial to date, randomized 654 children 2:1 to receive the VIASKIN Peanut Patch containing 250 µg of peanut protein (VP250) or placebo for 12 months. The study met its primary endpoint, with 46.6% of children in the VIASKIN Peanut Patch arm meeting treatment responder criteria at month 12 compared with 14.8% in the placebo arm (difference in response rates = 31.8%; 95% confidence interval [CI]: 24.5%, 39.0%; p<0.001).

“The VITESSE data presented at ACAAI add important context to the study’s overall positive results,” said Pharis Mohideen, M.D., Chief Medical Officer of DBV Technologies. “After one year of treatment, children receiving the VIASKIN® Peanut Patch in the study had statistically significantly lower maximum symptom severity during food challenge, along with immunologic changes consistent with other forms of allergen immunotherapy. I am also pleased that the practicality data show high treatment compliance in young children with common atopic comorbidities, and that all participants were able to continue their typical daily activities, including bathing, sports and swimming, while on treatment.”

Highlights from the VITESSE data presented at ACAAI 2026:
“Changes in Reaction Severity Following Epicutaneous Immunotherapy in Children with Peanut Allergy”

• At the month 12 double-blind, placebo-controlled food challenge (DBPCFC), maximum symptom severity was significantly lower with the VIASKIN^® Peanut Patch versus placebo (p=0.004). Severe reactions occurred in 8.4% of VIASKIN treated participants versus 12.5% of placebo participants; 12.5% of VIASKIN treated participants had no or mild symptoms versus 1.5% with placebo.
• When reactions at month 12 were evaluated at or below each participant’s baseline eliciting dose, 52.7% of VIASKIN treated participants had no symptoms versus 19.2% with placebo, while moderate or severe reactions occurred in 14.0% of VIASKIN treated participants versus 50.0% with placebo.

“Immunologic Changes in VITESSE: A 12-Month Study of Epicutaneous Immunotherapy in Children with Peanut Allergy”

• Peanut-specific IgG4 increased by month 3 with the VIASKIN® Peanut Patch and remained elevated through month 12
• At month 12, median peanut-specific IgE and Ara 2-specific IgE were significantly lower with the VIASKIN® Peanut Patch versus placebo (p=0.001).
• Mean skin-prick-test wheal diameter decreased significantly with the VIASKIN® Peanut Patch versus placebo at month 12 (least-squares mean ratio: 0.74; 95% CI: 0.69, 0.79; p<0.0001).
• VIASKIN® Peanut Patch treatment for one year resulted in statistically significant greater responder rates versus placebo and immunomodulatory changes consistent with other forms of allergen immunotherapy.

“Practicality of Daily Epicutaneous Immunotherapy in Young Children with Peanut Allergy”

• Mean treatment compliance was high in both groups (96.1% with the VIASKIN® Peanut Patch and 96.5% with placebo).
• Most patches were rated by participants as “very easy” or “easy” to remove (83.4% with the VIASKIN® Peanut Patch; 84.8% with placebo) and “not painful” to remove (71.9% with the VIASKIN® Peanut Patch; 70.2% with placebo).
• Participants continued typical daily activities, including bathing/showering, play, sports and swimming, with no restrictions on daily activities or concomitant medication use required during the study.
• Atopic comorbidities were common among VITESSE participants, including atopic dermatitis, other food allergies and asthma.

“When I work with families in the clinic, the treatment conversations are not just about safety and efficacy, but practical considerations such as time commitment, how a treatment might fit into family life and family routines, and impact on the child,” said Edwin H. Kim, M.D., Associate Professor of Pediatrics at the University of North Carolina School of Medicine. “These additional data from VITESSE are clinically meaningful and I believe support the potential of the VIASKIN® Peanut Patch to be integrated into the daily routines of children living with peanut allergy, if approved.”

The presentations will be made available on the Scientific Publications & Presentations page on the Company’s website following presentation at the meeting.

About DBV Technologies
DBV Technologies is a late-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary VIASKIN^® patch technology to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT), the VIASKIN^® patch is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of VIASKIN Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).

DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing five ordinary shares) are traded on the Nasdaq Capital Market (Ticker: DBVT; CUSIP: 23306J309).

For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.

VIASKIN is a registered trademark of DBV Technologies.

Forward Looking Statements
This press release may contain forward-looking statements, including statements regarding the therapeutic potential of VIASKIN^® Peanut patch and EPIT, designs of DBV’s anticipated clinical trials, DBV’s planned regulatory and clinical efforts including timing and results of communications with regulatory agencies, clinical trial data release and publications, , and the ability of any of DBV’s product candidates, if approved, to improve the lives of patients with food allergies. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. At this stage, DBV’s product candidates have not been authorized for sale in any country. Among the factors that could cause actual results to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals, and DBV’s ability to successfully execute on its budget discipline measures. A further list and description of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV’s regulatory filings with the U.S. Securities and Exchange Commission (“SEC”), including in DBV’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 26, 2026, as amended by the Amendment No. 1 on Form 10-K/A filed with the SEC on April 30, 2026, DBV’s Quarterly Report on Form 10-Q filed with the SEC on October 28, 2026, and future filings and reports made with the SEC by DBV. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.

Investor Contact
Virginie Boucinha
DBV Technologies
Virginie.Boucinha@dbv-technologies.com

Media Contact
Brett Whelan
DBV Technologies
brett.whelan@dbv-technologies.com

Attachment

• PDF Version

Open-architecture platform enables multi-chemistry battery sourcing; AI-enabled sales engine and partner portal built to accelerate backlog growth and convert backlog into revenue

Boca Raton, FL, Nov. 12, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary NOMAD Transportable Power Systems, a manufacturer of transportable, utility-grade battery energy storage systems, today provided an operational update ahead of its Q1 2027 production ramp.

Highlights

• Supply chain secured for Q1 ramp: NOMAD has firmed up component supply for its Q1 2027 ramp program.
• Open architecture delivering value: NOMAD’s platform is sourcing multiple battery types, allowing the Company to adopt newer cell technologies faster.
• AI-enabled sales engine: NOMAD has automated its sales outreach and proposal tracking with AI, integrated with a new partner and agency portal.
• Utility RFPs up 150%: Utility requests for proposal increased 150% over the prior quarter, driven by exposure from NOMAD’s fall roadshows.

Supply Chain Secured for the Q1 Ramp

NOMAD has firmed up supply for its Q1 2027 ramp program, including [battery modules, power conversion systems, enclosures and other long-lead components]. Locking in supply ahead of the ramp lets NOMAD quote utility and commercial customers with committed delivery windows and pricing, which are central to how utilities evaluate and award RFPs.

Open Architecture: More Battery Options, Faster

NOMAD’s Voyager platform was designed with an open architecture that is not tied to a single cell supplier or chemistry. That design is already paying off: NOMAD is qualifying and sourcing multiple battery types and can bring newer, higher-performing cell technologies into production faster than a closed system allows. The approach reduces single-source supply risk, keeps cost per kWh competitive, and gives NOMAD flexibility to meet customer and sourcing requirements as they evolve.

AI-Enabled Sales Outreach and Partner Portal

NOMAD has automated its sales outreach and proposal tracking using AI, giving the Company end-to-end visibility from first contact through RFP response, proposal and purchase order. The system is integrated with a new partner and agency portal that connects NOMAD’s independent sales representatives, which together field 43 utility sales professionals across 26 states and Washington, D.C., with shared lead management, proposal status and quoting. The result is faster response times, consistent proposals and a clear view of conversion across the pipeline.

Utility RFPs Up 150% on Roadshow Exposure

Utility RFPs received by NOMAD increased 150% over the prior quarter. The Company attributes the increase to greater market exposure from its fall roadshows, which brought Voyager systems to 26 stops across three regions: the Mountain West, New England and the Mid-Atlantic, and the Southwest. The roadshows put NOMAD’s transportable systems in front of utility engineers, procurement teams and the representative firms that call on them.

Backlog: Grow It Aggressively, Convert It to Revenue

NOMAD’s priority for the coming quarters runs on two tracks at once: aggressively growing backlog and converting existing backlog into revenue. Backlog is NOMAD’s forward indicator of revenue to come, and RFPs are the forward indicator of backlog. Utility procurement typically moves from RFP to award in four to five months, and from order to delivery in approximately six months, depending on site readiness. The 150% increase in utility RFPs this quarter positions NOMAD for awards in the first half of 2027.

Master service agreements multiply the value of each award. Once an MSA is executed, it allows continuous, ongoing purchasing of NOMAD units, and often other related products, under the same agreement.

Growing backlog

• Roadshows and a 43-professional utility sales network are feeding a larger, faster-growing RFP pipeline.
• AI-enabled outreach scales NOMAD’s reach across utilities, municipalities and data center customers without adding overhead.
• Open architecture keeps every bid competitive on price and technology.

Converting backlog to revenue

• Secured Q1 supply lets NOMAD commit to delivery dates and ship against orders on schedule.
• AI-enabled proposal tracking gives management line of sight from RFP to purchase order to delivery and revenue.

NOMAD previously announced backlog of more than $30 million. The Company will report backlog at least quarterly, and more frequently when it books materially large increases.

Management Commentary

“Backlog is the clearest forward indicator of our revenue, and we are running hard on two fronts: growing it as fast as we can and converting it into deliveries,” said John Travaglini, CEO of NOMAD Transportable Power Systems. “A 150% increase in utility RFPs tells us the roadshows put Voyager in front of the right buyers. With our Q1 supply chain locked in, we can commit to delivery dates and win those bids, and every win we ship moves backlog into revenue.”

“The demand is there. Our job now is to build backlog fast and turn it into revenue,” said Michael Hilmer, Executive Chairman of NOMAD Power Solutions.

About NOMAD Power Solutions, Inc.

NOMAD Power Solutions, Inc. (Nasdaq: NMAD) is an energy infrastructure equipment and services company focused on the design, manufacture and deployment of transportable, utility-grade power and energy-storage systems. Through its NOMAD Transportable Power Systems subsidiary, the Company markets its systems under the Voyager platform. NOMAD’s systems are engineered to provide rapidly deployable, relocatable power capacity for utility, commercial, industrial and other applications where grid capacity is unavailable, constrained or uneconomical. For more information, visit www.nomadpower.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical fact, including statements regarding NOMAD’s Q1 2027 production ramp, supply chain, the sourcing and adoption of battery technologies, the performance of its sales and partner systems, the timing of awards and deliveries, the conversion of RFPs into orders and backlog, future purchases under master service agreements, the frequency of backlog reporting, future backlog growth, and future customer demand, are forward-looking statements. These statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “will,” “plan,” “potential,” and similar expressions. Forward-looking statements are subject to risks and uncertainties, many of which are beyond NOMAD’s control, that could cause actual results to differ materially, including risks related to supply chain and manufacturing execution; supplier performance and component availability; qualification of new battery technologies; the timing and outcome of utility procurement processes; the performance of independent sales representatives; market acceptance of transportable energy storage; competition; and other risks described in NOMAD Power Solutions’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. NOMAD Power Solutions undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor Contact
Todd Kehrli, PondelWilkinson Inc. (310) 279-5961 | tkehrli@pondel.com

Media Contact
Stephen Johnson, Marketing Manager, NOMAD Transportable Power Systems, sjohnson@nomadpower.com

Open-architecture platform enables multi-chemistry battery sourcing; AI-enabled sales engine and partner portal built to accelerate backlog growth and convert backlog into revenue

Boca Raton, FL, Nov. 12, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary NOMAD Transportable Power Systems, a manufacturer of transportable, utility-grade battery energy storage systems, today provided an operational update ahead of its Q1 2027 production ramp.

Highlights

• Supply chain secured for Q1 ramp: NOMAD has firmed up component supply for its Q1 2027 ramp program.
• Open architecture delivering value: NOMAD’s platform is sourcing multiple battery types, allowing the Company to adopt newer cell technologies faster.
• AI-enabled sales engine: NOMAD has automated its sales outreach and proposal tracking with AI, integrated with a new partner and agency portal.
• Utility RFPs up 150%: Utility requests for proposal increased 150% over the prior quarter, driven by exposure from NOMAD’s fall roadshows.

Supply Chain Secured for the Q1 Ramp

NOMAD has firmed up supply for its Q1 2027 ramp program, including [battery modules, power conversion systems, enclosures and other long-lead components]. Locking in supply ahead of the ramp lets NOMAD quote utility and commercial customers with committed delivery windows and pricing, which are central to how utilities evaluate and award RFPs.

Open Architecture: More Battery Options, Faster

NOMAD’s Voyager platform was designed with an open architecture that is not tied to a single cell supplier or chemistry. That design is already paying off: NOMAD is qualifying and sourcing multiple battery types and can bring newer, higher-performing cell technologies into production faster than a closed system allows. The approach reduces single-source supply risk, keeps cost per kWh competitive, and gives NOMAD flexibility to meet customer and sourcing requirements as they evolve.

AI-Enabled Sales Outreach and Partner Portal

NOMAD has automated its sales outreach and proposal tracking using AI, giving the Company end-to-end visibility from first contact through RFP response, proposal and purchase order. The system is integrated with a new partner and agency portal that connects NOMAD’s independent sales representatives, which together field 43 utility sales professionals across 26 states and Washington, D.C., with shared lead management, proposal status and quoting. The result is faster response times, consistent proposals and a clear view of conversion across the pipeline.

Utility RFPs Up 150% on Roadshow Exposure

Utility RFPs received by NOMAD increased 150% over the prior quarter. The Company attributes the increase to greater market exposure from its fall roadshows, which brought Voyager systems to 26 stops across three regions: the Mountain West, New England and the Mid-Atlantic, and the Southwest. The roadshows put NOMAD’s transportable systems in front of utility engineers, procurement teams and the representative firms that call on them.

Backlog: Grow It Aggressively, Convert It to Revenue

NOMAD’s priority for the coming quarters runs on two tracks at once: aggressively growing backlog and converting existing backlog into revenue. Backlog is NOMAD’s forward indicator of revenue to come, and RFPs are the forward indicator of backlog. Utility procurement typically moves from RFP to award in four to five months, and from order to delivery in approximately six months, depending on site readiness. The 150% increase in utility RFPs this quarter positions NOMAD for awards in the first half of 2027.

Master service agreements multiply the value of each award. Once an MSA is executed, it allows continuous, ongoing purchasing of NOMAD units, and often other related products, under the same agreement.

Growing backlog

• Roadshows and a 43-professional utility sales network are feeding a larger, faster-growing RFP pipeline.
• AI-enabled outreach scales NOMAD’s reach across utilities, municipalities and data center customers without adding overhead.
• Open architecture keeps every bid competitive on price and technology.

Converting backlog to revenue

• Secured Q1 supply lets NOMAD commit to delivery dates and ship against orders on schedule.
• AI-enabled proposal tracking gives management line of sight from RFP to purchase order to delivery and revenue.

NOMAD previously announced backlog of more than $30 million. The Company will report backlog at least quarterly, and more frequently when it books materially large increases.

Management Commentary

“Backlog is the clearest forward indicator of our revenue, and we are running hard on two fronts: growing it as fast as we can and converting it into deliveries,” said John Travaglini, CEO of NOMAD Transportable Power Systems. “A 150% increase in utility RFPs tells us the roadshows put Voyager in front of the right buyers. With our Q1 supply chain locked in, we can commit to delivery dates and win those bids, and every win we ship moves backlog into revenue.”

“The demand is there. Our job now is to build backlog fast and turn it into revenue,” said Michael Hilmer, Executive Chairman of NOMAD Power Solutions.

About NOMAD Power Solutions, Inc.

NOMAD Power Solutions, Inc. (Nasdaq: NMAD) is an energy infrastructure equipment and services company focused on the design, manufacture and deployment of transportable, utility-grade power and energy-storage systems. Through its NOMAD Transportable Power Systems subsidiary, the Company markets its systems under the Voyager platform. NOMAD’s systems are engineered to provide rapidly deployable, relocatable power capacity for utility, commercial, industrial and other applications where grid capacity is unavailable, constrained or uneconomical. For more information, visit www.nomadpower.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical fact, including statements regarding NOMAD’s Q1 2027 production ramp, supply chain, the sourcing and adoption of battery technologies, the performance of its sales and partner systems, the timing of awards and deliveries, the conversion of RFPs into orders and backlog, future purchases under master service agreements, the frequency of backlog reporting, future backlog growth, and future customer demand, are forward-looking statements. These statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “will,” “plan,” “potential,” and similar expressions. Forward-looking statements are subject to risks and uncertainties, many of which are beyond NOMAD’s control, that could cause actual results to differ materially, including risks related to supply chain and manufacturing execution; supplier performance and component availability; qualification of new battery technologies; the timing and outcome of utility procurement processes; the performance of independent sales representatives; market acceptance of transportable energy storage; competition; and other risks described in NOMAD Power Solutions’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. NOMAD Power Solutions undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor Contact
Todd Kehrli, PondelWilkinson Inc. (310) 279-5961 | tkehrli@pondel.com

Media Contact
Stephen Johnson, Marketing Manager, NOMAD Transportable Power Systems, sjohnson@nomadpower.com

Open-architecture platform enables multi-chemistry battery sourcing; AI-enabled sales engine and partner portal built to accelerate backlog growth and convert backlog into revenue

Boca Raton, FL, Nov. 12, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), through its wholly owned subsidiary NOMAD Transportable Power Systems, a manufacturer of transportable, utility-grade battery energy storage systems, today provided an operational update ahead of its Q1 2027 production ramp.

Highlights

• Supply chain secured for Q1 ramp: NOMAD has firmed up component supply for its Q1 2027 ramp program.
• Open architecture delivering value: NOMAD’s platform is sourcing multiple battery types, allowing the Company to adopt newer cell technologies faster.
• AI-enabled sales engine: NOMAD has automated its sales outreach and proposal tracking with AI, integrated with a new partner and agency portal.
• Utility RFPs up 150%: Utility requests for proposal increased 150% over the prior quarter, driven by exposure from NOMAD’s fall roadshows.

Supply Chain Secured for the Q1 Ramp

NOMAD has firmed up supply for its Q1 2027 ramp program, including [battery modules, power conversion systems, enclosures and other long-lead components]. Locking in supply ahead of the ramp lets NOMAD quote utility and commercial customers with committed delivery windows and pricing, which are central to how utilities evaluate and award RFPs.

Open Architecture: More Battery Options, Faster

NOMAD’s Voyager platform was designed with an open architecture that is not tied to a single cell supplier or chemistry. That design is already paying off: NOMAD is qualifying and sourcing multiple battery types and can bring newer, higher-performing cell technologies into production faster than a closed system allows. The approach reduces single-source supply risk, keeps cost per kWh competitive, and gives NOMAD flexibility to meet customer and sourcing requirements as they evolve.

AI-Enabled Sales Outreach and Partner Portal

NOMAD has automated its sales outreach and proposal tracking using AI, giving the Company end-to-end visibility from first contact through RFP response, proposal and purchase order. The system is integrated with a new partner and agency portal that connects NOMAD’s independent sales representatives, which together field 43 utility sales professionals across 26 states and Washington, D.C., with shared lead management, proposal status and quoting. The result is faster response times, consistent proposals and a clear view of conversion across the pipeline.

Utility RFPs Up 150% on Roadshow Exposure

Utility RFPs received by NOMAD increased 150% over the prior quarter. The Company attributes the increase to greater market exposure from its fall roadshows, which brought Voyager systems to 26 stops across three regions: the Mountain West, New England and the Mid-Atlantic, and the Southwest. The roadshows put NOMAD’s transportable systems in front of utility engineers, procurement teams and the representative firms that call on them.

Backlog: Grow It Aggressively, Convert It to Revenue

NOMAD’s priority for the coming quarters runs on two tracks at once: aggressively growing backlog and converting existing backlog into revenue. Backlog is NOMAD’s forward indicator of revenue to come, and RFPs are the forward indicator of backlog. Utility procurement typically moves from RFP to award in four to five months, and from order to delivery in approximately six months, depending on site readiness. The 150% increase in utility RFPs this quarter positions NOMAD for awards in the first half of 2027.

Master service agreements multiply the value of each award. Once an MSA is executed, it allows continuous, ongoing purchasing of NOMAD units, and often other related products, under the same agreement.

Growing backlog

• Roadshows and a 43-professional utility sales network are feeding a larger, faster-growing RFP pipeline.
• AI-enabled outreach scales NOMAD’s reach across utilities, municipalities and data center customers without adding overhead.
• Open architecture keeps every bid competitive on price and technology.

Converting backlog to revenue

• Secured Q1 supply lets NOMAD commit to delivery dates and ship against orders on schedule.
• AI-enabled proposal tracking gives management line of sight from RFP to purchase order to delivery and revenue.

NOMAD previously announced backlog of more than $30 million. The Company will report backlog at least quarterly, and more frequently when it books materially large increases.

Management Commentary

“Backlog is the clearest forward indicator of our revenue, and we are running hard on two fronts: growing it as fast as we can and converting it into deliveries,” said John Travaglini, CEO of NOMAD Transportable Power Systems. “A 150% increase in utility RFPs tells us the roadshows put Voyager in front of the right buyers. With our Q1 supply chain locked in, we can commit to delivery dates and win those bids, and every win we ship moves backlog into revenue.”

“The demand is there. Our job now is to build backlog fast and turn it into revenue,” said Michael Hilmer, Executive Chairman of NOMAD Power Solutions.

About NOMAD Power Solutions, Inc.

NOMAD Power Solutions, Inc. (Nasdaq: NMAD) is an energy infrastructure equipment and services company focused on the design, manufacture and deployment of transportable, utility-grade power and energy-storage systems. Through its NOMAD Transportable Power Systems subsidiary, the Company markets its systems under the Voyager platform. NOMAD’s systems are engineered to provide rapidly deployable, relocatable power capacity for utility, commercial, industrial and other applications where grid capacity is unavailable, constrained or uneconomical. For more information, visit www.nomadpower.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical fact, including statements regarding NOMAD’s Q1 2027 production ramp, supply chain, the sourcing and adoption of battery technologies, the performance of its sales and partner systems, the timing of awards and deliveries, the conversion of RFPs into orders and backlog, future purchases under master service agreements, the frequency of backlog reporting, future backlog growth, and future customer demand, are forward-looking statements. These statements are often identified by words such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “may,” “will,” “plan,” “potential,” and similar expressions. Forward-looking statements are subject to risks and uncertainties, many of which are beyond NOMAD’s control, that could cause actual results to differ materially, including risks related to supply chain and manufacturing execution; supplier performance and component availability; qualification of new battery technologies; the timing and outcome of utility procurement processes; the performance of independent sales representatives; market acceptance of transportable energy storage; competition; and other risks described in NOMAD Power Solutions’ filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. You should not place undue reliance on forward-looking statements, which speak only as of the date of this release. NOMAD Power Solutions undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.

Investor Contact
Todd Kehrli, PondelWilkinson Inc. (310) 279-5961 | tkehrli@pondel.com

Media Contact
Stephen Johnson, Marketing Manager, NOMAD Transportable Power Systems, sjohnson@nomadpower.com

UAB “Atsinaujinančios energetikos investicijos” (hereinafter, the “Company”) hereby informs that the meeting of holders of notes of the Company, ISIN LT0000135840 (hereinafter, the “Notes”), dated 12 November 2026 approved the following proposals, provided by the Company (hereinafter, the “Proposals”):

1. The Maturity Date of the Notes is prolonged from 4 December 2026 to 4 December 2027.

2. The Interest Rate of the Notes is increased from 8.50% per annum to 10.00% per annum, as from 5 December 2026 and until the Maturity Date on 4 December 2027.

3. The Issuer is provided with a call option to redeem part or all of the Notes any date before the Maturity Date at 100% of nominal value of the Notes plus accrued interest, to be exercised following the order, described in the Terms and Conditions.

Necessary consequential changes will be made to the Final Terms of the Notes to implement the Proposals.

The Company hereby informs that it will take all the needed actions and execute all the needed documents, that its aforementioned provided and Noteholders’ approved Proposals were duly formalised and reflected in Nasdaq CSD SE and AB Nasdaq Vilnius systems.

Contact person for further information:
Mantas Auruškevičius
Manager of the Investment Company
mantas.auruskevicius@lordslb.lt

Attachment

• Final Terms (AEI) (2026-11-12)